Conference Call Details:
US/Canada Participant Toll-Free Dial-In Number: (833) 614-1551
US/Canada Participant International Dial-In Number: (914) 987-7290
United Kingdom International Dial-In Number: 0800 0288 438
United Kingdom Local Dial-In Number: 0203 1070 289
Conference ID: 1546327
Webcast Registration link: https://edge.media-server.com/mmc/p/y3zwhkuk
For further information, please contact: | ||
Renalytix plc | www.renalytix.com | |
Via Walbrook PR | ||
Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 | |
Tel: 020 7597 4000 | ||
Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com | |
Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 | ||
Tel: 415-389-6400 or investors@renalytix.com | ||
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX™, has been granted Breakthrough Designation by the
Source:
2022 GlobeNewswire, Inc., source